A new oral medication, orforglipron, has demonstrated superior results compared to semaglutide tablets in a large-scale clinical trial, potentially offering a more effective option for managing type 2 diabetes and obesity. The findings, published by researchers funded by Eli Lilly, suggest that orforglipron could become a leading alternative to injectable GLP-1 drugs like Ozempic and Wegovy.
How Orforglipron Works
GLP-1 (glucagon-like peptide-1) medications mimic a natural hormone that regulates appetite and boosts insulin production. Semaglutide, a highly successful GLP-1 drug, is most potent when injected but also available in pill form. Orforglipron aims to improve upon oral GLP-1 treatment, and the latest data suggests it succeeds.
Trial Results: Superior Blood Sugar Control and Weight Loss
The phase 3 trial involved 1,698 participants with type 2 diabetes. Those taking orforglipron experienced greater improvements in blood sugar levels and achieved more significant weight loss—an average of 6–8%—compared to the 4–5% weight loss observed in those taking semaglutide tablets.
According to the researchers, “Together with previous research, the results of the ACHIEVE-3 study suggest that orforglipron represents an important advancement in the oral treatment landscape for type 2 diabetes.” This builds upon earlier trials, including one from last year that compared orforglipron to a placebo.
Key Advantages Over Existing Treatments
Orforglipron offers at least one major convenience advantage over semaglutide: it can be taken with food, making it easier for patients to adhere to treatment. However, the trial also revealed a higher rate of discontinuation among those taking orforglipron (9–10% versus 4–5% for semaglutide) due to gastrointestinal side effects.
The study notes that while the safety profiles of both drugs are consistent with GLP-1 agonists, orforglipron was associated with more frequent gastrointestinal issues, higher discontinuation rates, and a slight increase in pulse rate.
What This Means for Diabetes and Obesity Treatment
Phase 3 trials, like this one conducted across 131 research centers over a year, are crucial steps toward drug approval. Orforglipron is now being evaluated by regulators, with plans to explore its potential as an obesity treatment in the future.
The results further support the growing body of evidence that GLP-1 drugs offer multiple health benefits. However, it’s crucial to remember that existing medications such as Wegovy have also been linked to serious side effects, including mental health issues and pancreatic damage.
Patient safety remains a priority, and trials like this help map the trade-offs between effectiveness and risk so doctors and regulators can make informed decisions. Orforglipron shows potential to be even more effective than semaglutide, but thorough evaluation is critical before widespread availability.
